Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 96 от 100

Активно (без набиране) Фаза 3

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Biliary Tract Cancer

A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.

Начало: 16.08.2023 Край: 17.09.2026 Възраст: 18–130 г.

France, Germany, Italy +5 AstraZeneca NCT05771480

Активно (без набиране) Фаза 2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma Head and Neck Cancer

This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Начало: 21.07.2023 Край: 28.05.2026 Възраст: от 18 г. Лечение

Australia, Canada, China +11 BeiGene NCT05909904

Активно (без набиране) Фаза 2

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Esophageal Adenocarcinoma Esophageal Cancer HER-2 Protein Overexpression Gastroesophageal-junction Cancer

An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esophagogastric adenocarcinoma who have completed chemoradiation followed by esophagectomy.

Начало: 14.07.2023 Край: 01.05.2026 Възраст: от 18 г.

United States Brown University NCT05480384

Активно (без набиране) Фаза 1

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

Melanoma Non Small Cell Lung Cancer Head and Neck Squamous Cell Carcinoma High Grade Serous Adenocarcinoma of Ovary +13

AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody. This is a dose escalation study to identify the maximum toxicity dose (MTD) or the recommended phase 2 dose (RP2D).

Начало: 11.07.2023 Край: 31.07.2026 Възраст: от 18 г. Лечение

Australia OncoC4, Inc. NCT05858736

Активно (без набиране) Фаза 1

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Melanoma Urothelial Carcinoma Renal Cell Carcinoma Non-small Cell Lung Cancer +2

Safety study of RC198 in Subjects with Solid Tumors.

Начало: 05.06.2023 Край: 31.12.2024 Възраст: от 18 г. Лечение

Australia, China RemeGen Co., Ltd. NCT05867303

Активно (без набиране) Фаза 2

Deep sequencIng in Cutaneous Squamous CEll caRciNomas

Cutaneous Squamous Cell Carcinoma Cutaneous Squamous Cell Carcinoma of the Head and Neck Neoplasms Non-melanoma Skin Cancer

To comprehensively describe the molecular profile of the tumour ecosystem of cutaneous squamous cell carcinoma (CSCC) patients treated with neoadjuvant immunotherapy using single-cell sequencing and bulk genomic profiling.

Начало: 26.05.2023 Край: 01.05.2029 Възраст: от 18 г. Друго

Australia Peter MacCallum Cancer Centre, Australia NCT05878288

Активно (без набиране)

Comprehensive Prospective Comparison Of Two Robotic Platforms In Anatomical Lung Resections: Clinical Outcomes And Cost-utility Analysis

Pulmonary Nodule, Solitary Lung Cancer (NSCLC) Pulmonary Metastases

The goal is to compare clinical outcomes, hospital costs, and cost-utility in patients undergoing anatomical lung resections with DaVinci Xi vs Versius platforms The main questions it aims to answer are: * Do patients that undergo an anatomical lung resection with DaVinci Xi have the same clinical outcomes (complications, stay...) than those who were operated with Versius? * Are anatomical lung resections performed with DaVinci Xi more expensive than those performed with Versius? * Are anatomical lung resection performed with DaVinci Xi more cost-effective than those performed with Versius? Participants already undergoing robotic anatomical lung resection as part of their regular medical care will answer quality of life questionnaires preoperatively, at 1, 3, 6, and 12 months after surgery.

Начало: 01.04.2023 Край: 31.07.2026 Възраст: от 18 г.

Spain Fundacion para la Investigacion Biomedica del Hospital NCT07537556

Активно (без набиране) Фаза 1

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Cutaneous Melanoma Non-small Cell Lung Cancer Colorectal Neoplasms Pancreatic Neoplasms +1

This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much PF-08046049/SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor cancers.

Начало: 03.01.2023 Край: 06.06.2026 Възраст: от 18 г.

Canada, France, Germany +3 Seagen, a wholly owned subsidiary of Pfizer NCT05571839

Активно (без набиране) Фаза 1/2

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Locally Advanced Urothelial Carcinoma Metastatic Urothelial Carcinoma Solid Tumor Urothelial Carcinoma +10

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.

Начало: 22.11.2022 Край: 01.06.2027 Възраст: от 18 г. Лечение

Australia, France, Spain +1 Tyra Biosciences, Inc NCT05544552

Активно (без набиране)

Fully Constrained Acetabular Liner vs. Dual Mobility Hip Joint in the Surgical Treatment of Metastatic Bone Disease of the Hip

Metastatic Cancer to the Hip

The purpose of the current study is to investigate whether dual mobility liners are non-inferior til constrained liners regarding the post-operative hip joint dislocation risk following total hip replacement in patients with metastatic bone disease of the hip.

Начало: 20.09.2022 Край: 22.04.2028 Възраст: от 18 г.

Denmark Rigshospitalet, Denmark NCT05461313

Активно (без набиране) Фаза 1

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Non-Small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma Advanced Solid Tumor

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.

Начало: 19.09.2022 Край: 30.09.2027 Възраст: от 18 г. Лечение

Australia, Czechia, France +10 Revolution Medicines, Inc. NCT05462717

Активно (без набиране)

Clinical Outcomes and Patient Satisfaction With Use of the Amma System

Breast Cancer

The primary goal is to conduct a pilot evaluation of the Amma device, to determine whether it is feasible to offer as an option for patients within oncology suites within the PH\&S system.

Начало: 22.08.2022 Край: 01.12.2026 Възраст: от 18 г.

United States Providence Health & Services NCT05508984

Активно (без набиране) Фаза 1/2

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

Human Papilloma Virus HPV HPV Positive Oropharyngeal Squamous Cell Carcinoma Head and Neck Cancer

Doctors leading this study hope to learn about the safety and effectiveness of combining medications HB-201 and HB-202 (also known as TheraT® vectors) with chemotherapy using carboplatin and paclitaxel in the beginning of the study (induction) and if combining these medications can increase tumor shrinkage after therapy and reduce the amount of radiotherapy and chemotherapy that will later be needed. In addition, the study is looking at ways to reduce side effects overall using robotic surgery, chemotherapy and radiotherapy, or radiotherapy alone. Your participation in this research will last about 2 years. HB-201 and HB-202 are experimental (meaning the US Food and Drug Administration (FDA) has not approved these drugs), and therefore they can only be given in a research study.

Начало: 22.08.2022 Край: 01.01.2027 Възраст: от 18 г.

United States University of Chicago NCT05108870

Активно (без набиране) Фаза 1

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

Refractory Cancer Recurrent Cancer Solid Tumor, Adult Cancer

The goal of this clinical trial is to evaluate the safety, tolerability and initial anti-tumor activity of IMA401 as monotherapy or in combination with checkpoint inhibitor in patients with recurrent and/or refractory solid tumors. Patients' HLA status and expression of the MAGE-A4 and/or MAGE-A8 target in the tumor must be confirmed. Primary objective: * To determine the maximum tolerated dose and/or recommended dose for extension for IMA401 as monotherapy and in combination with pembrolizumab Secondary objectives: * To characterize the safety and tolerability of IMA401 as monotherapy and in combination with pembrolizumab * To evaluate initial anti-tumor activity of IMA401 as monotherapy and in combination with pembrolizumab * To describe the pharmacokinetics of IMA401 as monotherapy and in combination with pembrolizumab

Начало: 19.05.2022 Край: 01.12.2029 Възраст: от 18 г.

Germany Immatics Biotechnologies GmbH NCT05359445

Активно (без набиране) Фаза 3

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Advanced Gastrointestinal Stromal Tumors Metastatic Cancer

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 442 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating the potential for drug-drug interactions between CGT9486 and sunitinib in approximately 18 patients who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 patients who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of CGT9486 plus sunitinib to sunitinib alone with patients being randomized in a 1:1 manner. Additionally, a drug-drug interactions substudy will investigate the potential for CGT9486 to be a CYP3A4 inducer in approximately 16 patients who have received at least one prior line of therapy for GIST.

Начало: 14.04.2022 Край: 01.09.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +18 Cogent Biosciences, Inc. NCT05208047

Активно (без набиране) Фаза 3

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Gastric Cancer Gastroesophageal Junction Adenocarcinoma

The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS) in participants with FGFR2b ≥10% 2+/3+ tumor cell staining (FGFR2b ≥10% 2+/3+TC)

Начало: 07.03.2022 Край: 20.06.2026 Възраст: 18–100 г. Лечение

Argentina, Australia, Belgium +33 Amgen NCT05052801

Активно (без набиране) Фаза 1/2

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Advanced Solid Tumor Locally Advanced Solid Tumor Metastatic Solid Tumor Platinum-resistant Ovarian Cancer +9

TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2 β/γ as monotherapy or in combination therapy in adult participants with advanced or metastatic solid tumors. Given the unique PK profile enabled by the TransCon technology, TransCon IL-2 β/γ presents the opportunity to enhance the therapeutic index of current IL-2 therapy.

Начало: 11.01.2022 Край: 01.08.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +7 Ascendis Pharma Oncology Division A/S NCT05081609

Активно (без набиране) Фаза 2

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Ovarian Cancer

This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors. Enrollment will take place in two phases: a preliminary phase followed by a potential expansion phase.

Начало: 07.10.2021 Край: 30.05.2028 Възраст: от 18 г. Лечение

Australia, Canada, Czechia +10 Hoffmann-La Roche NCT04931342

Активно (без набиране) Фаза 3

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Advanced Malignancies NSCLC Ovarian Cancer Urothelial Cancer +1

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Начало: 29.09.2021 Край: 30.09.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +16 Pfizer NCT05059522

Активно (без набиране)

Laparoscopic Approach for Emergency Colon Resection

Laparoscopic Surgery Colorectal Cancer Colorectal Disorders Emergencies +2

This is a randomized, controlled, parallel, multicenter trial to compare post-operative complications and long-term results between open and laparoscopic technique in emergency colorectal surgery.

Начало: 17.09.2021 Край: 30.07.2031 Възраст: 18–100 г.

Finland Joint Authority for Päijät-Häme Social and Health Care NCT05005117

1 … 94 95 96 97 98 … 100